Cargando…

Capturing the real‐world benefit of residual β‐cell function during clinically important time‐periods in established Type 1 diabetes

AIMS: Many individuals with type 1 diabetes retain residual β‐cell function, with increased endogenous insulin secretion associated with reduced hyperglycaemia, hypoglycaemia and glycaemic variability. However, it is unknown when these improvements occur during the day. Dysglycaemia is common in ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Guy S., Shaw, Andy C., Smith, Kieran, Wason, James, McDonald, Timothy J., Oram, Richard A., Stevenson, Emma, Shaw, James A. M., West, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311680/
https://www.ncbi.nlm.nih.gov/pubmed/35181926
http://dx.doi.org/10.1111/dme.14814
_version_ 1784753652248870912
author Taylor, Guy S.
Shaw, Andy C.
Smith, Kieran
Wason, James
McDonald, Timothy J.
Oram, Richard A.
Stevenson, Emma
Shaw, James A. M.
West, Daniel J.
author_facet Taylor, Guy S.
Shaw, Andy C.
Smith, Kieran
Wason, James
McDonald, Timothy J.
Oram, Richard A.
Stevenson, Emma
Shaw, James A. M.
West, Daniel J.
author_sort Taylor, Guy S.
collection PubMed
description AIMS: Many individuals with type 1 diabetes retain residual β‐cell function, with increased endogenous insulin secretion associated with reduced hyperglycaemia, hypoglycaemia and glycaemic variability. However, it is unknown when these improvements occur during the day. Dysglycaemia is common in overnight and postprandial periods and associated with diabetes complications. Therefore, this study aimed to determine the influence of residual β‐cell function upon nocturnal and postprandial glycaemic control in established type 1 diabetes. METHODS: Under free‐living conditions, 66 participants wore a blinded continuous glucose monitor (CGM), kept a food diary, and completed a stimulated urine C‐peptide creatinine (UCPCR) test. Nocturnal, and postprandial CGM outcomes (participant means and discrete event analysis) were compared between UCPCR groups: undetectable (Cpep(und)), low (Cpep(low): 0.001–0.19 nmol/mmol) and high (Cpep(high): ≥0.2 nmol/mmol). RESULTS: Greater β‐cell function was associated with incremental improvements in glycaemia. Cpep(high) spent significantly greater time in normoglycaemia than Cpep(und) overnight (76 ± 20% vs. 58 ± 20%, p = 0.005) and 0–300 mins postprandially (68 ± 22% vs. 51 ± 22%, p = 0.045), while also having reducing nocturnal variability (SD 1.12 ± 0.41 vs. 1.52 ± 0.43 mmol/L, p = 0.010). Analysis of individual events, controlling for diabetes duration, BMI, basal insulin, use of a continuous or flash glucose monitor and (for postprandial) meal type, carbohydrate and bolus insulin intake, replicated the group findings, additionally demonstrating Cpep(und) had increased hyperglycaemia versus Cpep(low) overnight and increased postprandial hypoglycaemic events compared with Cpep(high). For all participants, breakfast had a significantly higher incremental area under the curve than lunch and dinner. CONCLUSIONS: Residual β‐cell function is associated with improved nocturnal and postprandial glycaemic control. These data may be of clinical importance for identifying specific periods and individuals where further glycaemic management strategies would be beneficial.
format Online
Article
Text
id pubmed-9311680
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93116802022-07-29 Capturing the real‐world benefit of residual β‐cell function during clinically important time‐periods in established Type 1 diabetes Taylor, Guy S. Shaw, Andy C. Smith, Kieran Wason, James McDonald, Timothy J. Oram, Richard A. Stevenson, Emma Shaw, James A. M. West, Daniel J. Diabet Med Research: Pathophysiology AIMS: Many individuals with type 1 diabetes retain residual β‐cell function, with increased endogenous insulin secretion associated with reduced hyperglycaemia, hypoglycaemia and glycaemic variability. However, it is unknown when these improvements occur during the day. Dysglycaemia is common in overnight and postprandial periods and associated with diabetes complications. Therefore, this study aimed to determine the influence of residual β‐cell function upon nocturnal and postprandial glycaemic control in established type 1 diabetes. METHODS: Under free‐living conditions, 66 participants wore a blinded continuous glucose monitor (CGM), kept a food diary, and completed a stimulated urine C‐peptide creatinine (UCPCR) test. Nocturnal, and postprandial CGM outcomes (participant means and discrete event analysis) were compared between UCPCR groups: undetectable (Cpep(und)), low (Cpep(low): 0.001–0.19 nmol/mmol) and high (Cpep(high): ≥0.2 nmol/mmol). RESULTS: Greater β‐cell function was associated with incremental improvements in glycaemia. Cpep(high) spent significantly greater time in normoglycaemia than Cpep(und) overnight (76 ± 20% vs. 58 ± 20%, p = 0.005) and 0–300 mins postprandially (68 ± 22% vs. 51 ± 22%, p = 0.045), while also having reducing nocturnal variability (SD 1.12 ± 0.41 vs. 1.52 ± 0.43 mmol/L, p = 0.010). Analysis of individual events, controlling for diabetes duration, BMI, basal insulin, use of a continuous or flash glucose monitor and (for postprandial) meal type, carbohydrate and bolus insulin intake, replicated the group findings, additionally demonstrating Cpep(und) had increased hyperglycaemia versus Cpep(low) overnight and increased postprandial hypoglycaemic events compared with Cpep(high). For all participants, breakfast had a significantly higher incremental area under the curve than lunch and dinner. CONCLUSIONS: Residual β‐cell function is associated with improved nocturnal and postprandial glycaemic control. These data may be of clinical importance for identifying specific periods and individuals where further glycaemic management strategies would be beneficial. John Wiley and Sons Inc. 2022-03-10 2022-05 /pmc/articles/PMC9311680/ /pubmed/35181926 http://dx.doi.org/10.1111/dme.14814 Text en © 2022 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research: Pathophysiology
Taylor, Guy S.
Shaw, Andy C.
Smith, Kieran
Wason, James
McDonald, Timothy J.
Oram, Richard A.
Stevenson, Emma
Shaw, James A. M.
West, Daniel J.
Capturing the real‐world benefit of residual β‐cell function during clinically important time‐periods in established Type 1 diabetes
title Capturing the real‐world benefit of residual β‐cell function during clinically important time‐periods in established Type 1 diabetes
title_full Capturing the real‐world benefit of residual β‐cell function during clinically important time‐periods in established Type 1 diabetes
title_fullStr Capturing the real‐world benefit of residual β‐cell function during clinically important time‐periods in established Type 1 diabetes
title_full_unstemmed Capturing the real‐world benefit of residual β‐cell function during clinically important time‐periods in established Type 1 diabetes
title_short Capturing the real‐world benefit of residual β‐cell function during clinically important time‐periods in established Type 1 diabetes
title_sort capturing the real‐world benefit of residual β‐cell function during clinically important time‐periods in established type 1 diabetes
topic Research: Pathophysiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311680/
https://www.ncbi.nlm.nih.gov/pubmed/35181926
http://dx.doi.org/10.1111/dme.14814
work_keys_str_mv AT taylorguys capturingtherealworldbenefitofresidualbcellfunctionduringclinicallyimportanttimeperiodsinestablishedtype1diabetes
AT shawandyc capturingtherealworldbenefitofresidualbcellfunctionduringclinicallyimportanttimeperiodsinestablishedtype1diabetes
AT smithkieran capturingtherealworldbenefitofresidualbcellfunctionduringclinicallyimportanttimeperiodsinestablishedtype1diabetes
AT wasonjames capturingtherealworldbenefitofresidualbcellfunctionduringclinicallyimportanttimeperiodsinestablishedtype1diabetes
AT mcdonaldtimothyj capturingtherealworldbenefitofresidualbcellfunctionduringclinicallyimportanttimeperiodsinestablishedtype1diabetes
AT oramricharda capturingtherealworldbenefitofresidualbcellfunctionduringclinicallyimportanttimeperiodsinestablishedtype1diabetes
AT stevensonemma capturingtherealworldbenefitofresidualbcellfunctionduringclinicallyimportanttimeperiodsinestablishedtype1diabetes
AT shawjamesam capturingtherealworldbenefitofresidualbcellfunctionduringclinicallyimportanttimeperiodsinestablishedtype1diabetes
AT westdanielj capturingtherealworldbenefitofresidualbcellfunctionduringclinicallyimportanttimeperiodsinestablishedtype1diabetes